Skip to main content

TIMM | Virtual | October 2021

By

TIMM Virtual | October 2021 Rezafungin safety and pharmacokinetics in subjects with moderate or severe hepatic impairment [335] Evaluation of the post-antifungal effect of rezafungin and micafungin against Candida albicans, Candida parapsilosis, and Candida glabrata [388]

Read More

IDWeek | Virtual | Sep-Oct 2021

By

IDWeek Virtual | Sep-Oct 2021 A Multicenter, Mixed-Method Evaluation of Delayed Hospital Discharge in Patients with Invasive Candidiasis Receiving Echinocandins [157] Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin [982] Activity of Rezafungin and Comparator Antifungal Agents Tested Against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019–2020) [1076]

Read More

ISHAM-Asia | Virtual | August 2021

By

ISHAM-Asia Virtual | August 2021 Activity of Rezafungin against Clinical Candida and Aspergillus spp. Isolates Collected in Asia-Pacific Countries (2014-2018) [ABST60] Rezafungin: A novel, once-weekly echinocandin in phase 3 development for treatment and prevention of invasive fungal disease [symposium presentation]

Read More

ECCMID | Virtual | July 2021

By

ECCMID Virtual | July 2021 Development and validation of a modified EUCAST yeast broth microdilution MIC method for rezafungin to mitigate nonspecific binding through incorporation of Tween 20 [01052] Analysis of Safety from STRIVE Phase 2 Trial of Rezafungin Treatment of Candidemia and/or Invasive Candidiasis: Assessment of Adverse Events and Laboratory Values [01672] Analysis of Efficacy from STRIVE Phase 2 Trial of Rezafungin Treatment of Candidemia and/or Invasive Candidiasis: Outcomes During Initial Days of Treatment…

Read More

ICHS SYMPOSIUM | VIRTUAL | February 2021

By

ICHS SYMPOSIUM VIRTUAL | February 2021 Efficacy and Safety By Renal Function in the Phase 2 STRIVE Trial of Rezafungin in Treatment of Candidemia and Invasive Candidiasis (IC) [Poster] Safety and Efficacy of Rezafungin in Immunocompromised Patients: Analysis of Outcomes from the Phase 2 STRIVE Trial of Rezafungin for Treatment of Candidemia and Invasive Candidiasis [Poster] Fungal Eradication With Extended Rezafungin Treatment In a Murine Model Of Pneumocystis Pneumonia [Poster] Rezafungin: Evidence and Experience to…

Read More

ESWI | VIRTUAL | December 2020

By

ESWI VIRTUAL | December 2020 In Vitro Potency and In Vivo Efficacy of CD377, a Novel Antiviral Fc-Conjugate, Against Highly Pathogenic Avian Influenza (HPAI) [139] Efficacy of CD377, a Novel Antiviral Fc-Conjugate, by Multiple Dosing Routes Against Influenza A (H1N1), and Activity Against Oseltamivir-Resistant Isolates in Lethal Mouse Models [159] Characterization of In Vitro Activity and In Vivo Efficacy of CD377, a Novel Antiviral Fc-Conjugate, Against 2020-2021 Northern Hemisphere Influenza Quadrivalent Vaccine Strains [269]

Read More

ESICM LIVES | VIRTUAL | December 2020

By

ESICM LIVES VIRTUAL | December 2020 Analysis of the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin: Outcomes by ICU Status and APACHE II Score Analysis of Outcomes by Geographic Region of Enrollment in STRIVE, the Phase 2 of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis (IC) [encore] Analysis of the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive…

Read More